eNeura Therapeutics Leadership

Robert Fischell (born 1929) is a physicist, prolific inventor, and holder of more than 200 U.S. and foreign medical patents. His inventions have led to the creation of several biotechnology companies. He worked at the Johns Hopkins University Applied Physics Laboratory full-time for 25 years, and part-time for an additional 13 years. He contributed to APL's satellite navigation work, and later developed a rechargeable implantable pacemaker that could be programmed with radiowaves, (Pacesetter Systems purchased by Siemens, now the CRM division of St. Jude Medical). He and his team at Hopkins also helped miniaturize the implantable cardiac defibrillator. Mr. Fischell went on to invent the implantable insulin pump (MiniMed, spun off from Pacesetter Systems in 1985), numerous coronary stents used to open clogged arteries (IsoStent merged with Cordis, in turn purchased by Johnson & Johnson), and two feedback systems that provide early warning of epileptic seizures (NeuroPace) and heart attacks (Angel Medical Systems). Fischell recently donated $30 million to the University of Maryland College Park Foundation to establish a bioengineering department and an institute for biomedical devices at the A. James Clark School of Engineering.

Accomplished, results driven healthcare entrepreneur with proven ability to exceed company goals through leadership, strategy and focused execution. Senior leadership experience: medical device, diagnostics, pharmaceuticals, digital therapeutics and telemedicine. Areas of expertise include:

Market Strategy & Development - Sales & Marketing Leadership - Business Development - Product Development - Communications & Branding - Data Analytics - Payer Access & Coverage Policy - Clinical & Economic Outcome Studies - Finance

Robert Fischell (born 1929) is a physicist, prolific inventor, and holder of more than 200 U.S. and foreign medical patents. His inventions have led to the creation of several biotechnology companies. He worked at the Johns Hopkins University Applied Physics Laboratory full-time for 25 years, and part-time for an additional 13 years. He contributed to APL's satellite navigation work, and later developed a rechargeable implantable pacemaker that could be programmed with radiowaves, (Pacesetter Systems purchased by Siemens, now the CRM division of St. Jude Medical). He and his team at Hopkins also helped miniaturize the implantable cardiac defibrillator. Mr. Fischell went on to invent the implantable insulin pump (MiniMed, spun off from Pacesetter Systems in 1985), numerous coronary stents used to open clogged arteries (IsoStent merged with Cordis, in turn purchased by Johnson & Johnson), and two feedback systems that provide early warning of epileptic seizures (NeuroPace) and heart attacks (Angel Medical Systems). Fischell recently donated $30 million to the University of Maryland College Park Foundation to establish a bioengineering department and an institute for biomedical devices at the A. James Clark School of Engineering.

Robert Fischell (born 1929) is a physicist, prolific inventor, and holder of more than 200 U.S. and foreign medical patents. His inventions have led to the creation of several biotechnology companies. He worked at the Johns Hopkins University Applied Physics Laboratory full-time for 25 years, and part-time for an additional 13 years. He contributed to APL's satellite navigation work, and later developed a rechargeable implantable pacemaker that could be programmed with radiowaves, (Pacesetter Systems purchased by Siemens, now the CRM division of St. Jude Medical). He and his team at Hopkins also helped miniaturize the implantable cardiac defibrillator. Mr. Fischell went on to invent the implantable insulin pump (MiniMed, spun off from Pacesetter Systems in 1985), numerous coronary stents used to open clogged arteries (IsoStent merged with Cordis, in turn purchased by Johnson & Johnson), and two feedback systems that provide early warning of epileptic seizures (NeuroPace) and heart attacks (Angel Medical Systems). Fischell recently donated $30 million to the University of Maryland College Park Foundation to establish a bioengineering department and an institute for biomedical devices at the A. James Clark School of Engineering.